SCHEMBL6286372

SCHEMBL6286372

CC(=O)CCC(=O)c1ccc(Br)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.57
KMT2A Q03164 5/20 0.54
MEN1 O00255 1/20 0.54
POLB P06746 1/20 0.54
HDAC1 Q13547 3/20 0.53
HDAC8 Q9BY41 3/20 0.53
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
HPGD P15428 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 1/20 0.53
HSD11B1 P28845 1/20 0.49
HSP90AA1 P07900 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL241664 0.89 GSK3B (0.70) GSK3BKMT2AMEN1POLBHDAC1
SCHEMBL11686001 0.89 SMN1; SMN2 (0.62) KMT2APOLBHPGDSMN1; SMN2KDM4E
SCHEMBL16499440 0.88 GSK3B (0.57) GSK3BKMT2AMEN1POLBHDAC1
SCHEMBL3141694 0.83 SMN1; SMN2 (0.56) KMT2APOLBHPGDSMN1; SMN2KDM4E
SCHEMBL2452141 0.82 HDAC1 (0.57) GSK3BKMT2AMEN1POLBHDAC1
SCHEMBL100952 0.81 NR4A2 (0.65) GSK3BKMT2AMEN1POLBHDAC1
SCHEMBL2116189 0.81 HSD17B3 (0.67) GSK3BKMT2AMEN1POLBHDAC1
SCHEMBL822848 0.81 KMT2A (0.70) GSK3BKMT2AMEN1POLBHPGD
SCHEMBL8532385 0.81 HSD17B3 (0.67) KMT2APOLBHPGDSMN1; SMN2KDM4E
SCHEMBL394576 0.81 GSK3B (0.59) GSK3BKMT2AMEN1POLBHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-12-23 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
CN-115028637-B Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2024-03-22 CN disclosed
US-11851432-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-12-26 US disclosed
US-20230192704-A1 MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF TEON THERAPEUTICS INC (US) 2023-06-22 US disclosed
US-20230192704-A1 MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF TEON THERAPEUTICS INC (US) 2023-06-22 US disclosed
US-20230192704-A1 MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF TEON THERAPEUTICS INC (US) 2023-06-22 US disclosed
EP-4153652-A1 MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF Teon Therapeutics, Inc. (US) 2023-03-29 EP disclosed
EP-3790879-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) 2021-03-17 EP disclosed
CN-112469721-A Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2021-03-09 CN disclosed
WO-2019215316-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2019-11-14 WO disclosed
WO-2019215316-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2019-11-14 WO disclosed
US-9862676-B2 Hydroxamic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2018-01-09 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
US-6911468-B2 Tyrosine phosphatase inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-06-28 US disclosed
US-20030144338-A1 Tyrosine phosphatase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-07-31 US disclosed
EP-1284260-A1 TYROSINE PHOSPHATASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2003-02-19 EP disclosed
EP-0885869-A1 THERAPEUTIC AGENT FOR DIABETES Japan Tobacco Inc. (JP) 1998-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144338-A1 Tyrosine phosphatase inhibitors PTPRC, PTPN1, PTPRM GSK3B 522/4885KMT2A 629/4885MEN1 2361/4885
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF H1-0, H1-2, HDAC1 GSK3B 4507/4885KMT2A 330/4885MEN1 1824/4885
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 GSK3B 1670/4885KMT2A 1533/4885MEN1 3154/4885
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 GSK3B 1670/4885KMT2A 1533/4885MEN1 3154/4885
US-11851432-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 GSK3B 1670/4885KMT2A 1533/4885MEN1 3154/4885
US-20230192704-A1 MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF SLC16A3, SLC16A1, SLC16A8 GSK3B 1468/4885KMT2A 2767/4885MEN1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.